DCE-MRI as Pazopanib Biomarker in Metastatic Renal Cancer
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics
- 12 Jun 2017 Status changed from completed to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 29 Jun 2016 Status changed from active, no longer recruiting to completed.